FDA finalizes REMS program for ESAs; Amgen continues to study risks.

Journal of the National Cancer Institute

Volumn 102, Issue 9, 2010, Pages 592-593

  Brower, Vicki ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; ERYTHROPOIETIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CHEMICALLY INDUCED DISORDER; FOOD AND DRUG ADMINISTRATION; HUMAN; METHODOLOGY; NOTE; PALLIATIVE THERAPY; RISK; UNITED STATES;

ANEMIA; ANTINEOPLASTIC AGENTS; EPOETIN ALFA; ERYTHROPOIETIN; HEMATINICS; HUMANS; PALLIATIVE CARE; RISK; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 77952304164     PISSN: None     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djq162     Document Type: Note

References (0)